8,078 TransMedics Group, Inc. $TMDX Shares Purchased by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC raised its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 30.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,986 shares of the company’s stock after purchasing an additional 8,078 shares during the period. TransMedics Group accounts for about 1.5% of Taylor Frigon Capital Management LLC’s holdings, making the stock its 20th biggest position. Taylor Frigon Capital Management LLC owned 0.10% of TransMedics Group worth $2,920,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ascentis Independent Advisors purchased a new stake in shares of TransMedics Group during the 1st quarter worth approximately $30,000. North Star Investment Management Corp. acquired a new position in shares of TransMedics Group in the 1st quarter valued at $30,000. Silvant Capital Management LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $26,000. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of TransMedics Group by 95.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock valued at $45,000 after buying an additional 207 shares in the last quarter. Finally, State of Wyoming acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $31,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill purchased 1,336 shares of TransMedics Group stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the transaction, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.90% of the stock is owned by insiders.

TransMedics Group Trading Down 1.8%

TMDX opened at $70.74 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The business’s 50 day moving average is $83.92 and its two-hundred day moving average is $81.96. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of 18.19, a price-to-earnings-growth ratio of 0.97 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 earnings per share. On average, research analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TMDX shares. Zacks Research downgraded shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research note on Friday, September 11th. Barclays began coverage on shares of TransMedics Group in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, UBS Group dropped their price objective on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $115.60.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.